Anacor Pharmaceuticals Reports 2015 Fourth Quarter and Year-End Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Jefferies Cuts Price Target on Anacor Pharma (ANAC) to $105 Following a 4Q EPS Miss
March 1, 2016 9:12 AM ESTJefferies maintained a Buy rating on Anacor Pharmaceuticals (NASDAQ: ANAC), and cut the price target to $105.00 (from $159.00), following the company's 4Q earnings report. ANAC reported an EPS loss of $0.43, missing Jefferies' estimates for a loss of $0.31. Management attributed the miss to short term competitive... More
Anacor Pharma (ANAC) Misses Q4 EPS by 13c
February 29, 2016 4:04 PM ESTAnacor Pharma (NASDAQ: ANAC) reported Q4 EPS of ($0.43), $0.13 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $21.2 million versus the consensus estimate of $27.93 million.
For earnings history and earnings-related data on Anacor Pharma (ANAC) click here.
... More